(Leqembi) … Treatment for Alzheimer's Disease Is Set to Launch in Germany

kreiszeitung.de

stern.de

View article

onetz.de

View article

mannheim24.de

View article

geo

View article

+4 Reposted by 4 other sources

Center

Factuality

Ownership

Lecanemab is supposed to help Alzheimer's in the early stages, but not all patients benefit. The therapy is expensive – and also carries risks.

saarbruecker-zeitung.de

Center

Factuality

Ownership

Lecanemab is supposed to help Alzheimer's in the early stages, but not all patients benefit. Therapy is expensive - and also carries risks.

aletihad.ae

Factuality

Ownership

Lecanemab, the approved drug for the treatment of Alzheimer's disease, will officially go on the German market on September 1. A statement issued by the two pharmaceutical companies involved in developing the drug, the US-based Biogen and the Japanese-based Eisai, stated that Austria and Germany are the first two countries in the European Union to launch the drug, marketed under the name Lecanemab. This treatment, which was approved after much h…

Deutsches Ärzteblatt

Factuality

Ownership

Berlin – With the market launch of lecanemab for the treatment of early Alzheimer's dementia, a drug that can slow the progression of the disease is available starting Monday. However, determining the indication and caring for patients taking lecanemab requires a great deal of effort in neurological and other practices. This...